Nautilus Biotechnology, Inc. (NAUT) Stock Price & Analysis
Nautilus Biotechnology, Inc. (NAUT) closed at USD 2.16 on Thursday, October 15, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.16; the Oct 15, 2026 session ranged USD 1.88–2.2 on volume of 8,502,195 shares. Market capitalization is $274.87M, with a 52-week range of USD 0.84–4.31 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NAUT.md
Key facts (NAUT)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 3.83 (range 3.5–4).
- Total return with dividends: 1Y +101.9% vs S&P 500 +18.1%; 5Y -62.2% vs S&P 500 +85.1%.
- Next earnings: 2026-10-27, EPS estimate USD -0.14, revenue estimate $206K.
Analysts (NAUT)
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 3.83 (low 3.5, high 4).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Roth Capital | Initiated | Buy | $3.5 |
| 2026-09-09 | Leerink Partners | Initiated | Outperform | $4 |
Total return (dividends reinvested) (NAUT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +101.9% | -62.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +102.4% | -17.6% |
| Volatility (annualized) | 117.0% | 78.4% |
| Max drawdown | -78.4% (Mar 2026→Aug 2026) | -89.1% (Dec 2021→Sep 2025) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 2.16 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 2.16 |
| Open | USD 2.07 |
| Day Range | USD 1.88 – 2.2 |
| 52-Week Range | USD 0.84 – 4.31 |
| Volume | 8,502,195 shares |
| Market Cap | $274.87M |
| Exchange | NCM |
Technical Analysis (NAUT)
Nexqual's technical model rates NAUT "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 69.85 (neutral) |
| vs SMA50 | Above (USD 1.18) |
| MACD | 0.3 (positive) |
Analyst Ratings (NAUT)
Wall Street analysts rate NAUT "Buy" based on 4 analysts, with a mean price target of USD 3.83 (range USD 3.5–4), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 3.83 |
| High Target | USD 4 |
| Low Target | USD 3.5 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (NAUT)
| Next Earnings Date | 2026-10-27 |
|---|---|
| Revenue Estimate | $206,250 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.11 vs est -0.14 ▲ beat |
| 2026-03-31 | USD -0.12 vs est -0.15 ▲ beat |
| 2025-12-31 | USD -0.11 vs est -0.14 ▲ beat |
| 2025-09-30 | USD -0.11 vs est -0.15 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (NAUT)
| Total Revenue | $190,000 |
|---|---|
| Gross Margin | +92.11% |
| Operating Margin | -8296.32% |
| Profit Margin | +0.00% |
| ROE | -36.21% |
| Debt / Equity | 0.21 |
| Current Ratio | 10.14 |
| Total Cash | $84.03M |
| Total Debt | $27.82M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (NAUT)
Nexqual rates Nautilus Biotechnology, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $84M cash vs $28M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$51M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -36%, ROA -20.8% |
Ownership (NAUT)
| Insider Ownership | +32.02% |
|---|---|
| Institutional Ownership | +43.04% |
| Shares Outstanding | 127.26M |
| Float | 67.47M |
| Short % of Float | +9.21% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (NAUT)
Nautilus Biotechnology, Inc. is led by Sujal M. Patel (age 50), Co-Founder, CEO, President, Secretary & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| Co-Founder, CEO, President, Secretary & Director | Sujal M. Patel (age 50) |
|---|---|
| Co-Founder, Chief Scientist & Director | Parag Mallick (age 47) |
| CFO & Treasurer | Anna Mowry (age 42) |
| Vice President of Global Sales | Amber Faust |
| Vice President of Marketing | Jamie Rose Kuhar |
Major Backers & Investors (NAUT)
Notable institutional backers of Nautilus Biotechnology, Inc. include Perceptive Advisors Llc, a16z Capital Management, L.L.C., Cercano Management Llc, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Perceptive Advisors Llc | 9.14% |
| a16z Capital Management, L.L.C. | 7.12% |
| Cercano Management Llc | 5.64% |
| Comprehensive Financial Management, LLC | 1.73% |
| Citadel | 1.49% |
| Acadian Asset Management. LLC | 0.83% |
| Clearstead Advisors, LLC | 0.7% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.95% |
| BlackRock | 3.37% |
| Geode Capital | 0.99% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt